GILEAD SCIENCES, INC. Gain (Loss) on Fair Value Hedges Recognized in Earnings
GILEAD SCIENCES, INC. (GILD) reported Gain (Loss) on Fair Value Hedges Recognized in Earnings of $128.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2018-02-27.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings · last filed 2018-02-27
- GILEAD SCIENCES, INC. gain (loss) on fair value hedges recognized in earnings for the quarter ending 2016-06-30 was $69.00M.
- GILEAD SCIENCES, INC. gain (loss) on fair value hedges recognized in earnings for the quarter ending 2016-03-31 was $59.00M.
- GILEAD SCIENCES, INC. gain (loss) on fair value hedges recognized in earnings for fiscal 2016 was $128.00M.
| Period end | Gain (Loss) on Fair Value Hedges Recognized in Earnings 3 month | Gain (Loss) on Fair Value Hedges Recognized in Earnings 6 month | Gain (Loss) on Fair Value Hedges Recognized in Earnings 12 month |
|---|---|---|---|
| 2016-12-31 | $128.00M 10-K · filed 2018-02-27 | ||
| 2016-06-30 | $69.00M 10-Q · filed 2016-11-07 | $128.00M derived: sum of 2 quarters · filed 2016-11-07 | |
| 2016-03-31 | $59.00M 10-Q · filed 2016-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |